Skip to main content
News

Dermacyte Matrix - Merakris Therapeutics

https://www.globenewswire.com/news-release/2025/03/26/3049447/0/en/International-Wound-Journal-Publishes-Positive-Phase-2-Interim-Data-on-Cell-free-Amniotic-Fluid-Injectable-Biologic-for-the-Treatment-of-Venous-Leg-Ulcers.html

Merakris Therapeutics announced positive results from a Phase 2 study evaluating Dermacyte Liquid (MTX-001), a subcutaneous amniotic fluid product for refractory VLUs. Of the nine patients, 66.7% of patients achieved complete closure at one month follow-up.